| [1] |
Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804.
|
| [2] |
Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182.
|
| [3] |
Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer[J]. Annu Rev Pathol, 2022, 17: 181-204.
|
| [4] |
Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer[J]. J Hematol Oncol, 2022, 15(1): 121.
|
| [5] |
Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-1198.
|
| [6] |
Jabbarzadeh Kaboli P, Shabani S, Sharma S, et al. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates[J]. Am J Cancer Res, 2022, 12(4): 1671-1685.
|
| [7] |
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.
|
| [8] |
Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541.
|
| [9] |
Xu B, Ma F, Wang T, et al. A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J]. Int J Cancer, 2023, 152(10): 2134-2144.
|
| [10] |
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.
|
| [11] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021版)[J]. 中国癌症杂志，2021, 31(10)：1007-3639.
|
| [12] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2022版)[M]. 北京：人民卫生出版社，2022.
|
| [13] |
European Society for Medical Oncology. ESMO metastatic breast cancer living guideline[EB/OL].[2024-03-15].
URL
|
| [14] |
Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J]. Mol Cancer Ther, 2021, 20(12): 2329-2340.
|
| [15] |
Aditya B, lan EK, Funda MB, et al. Datopotamab deruxtecan (Dato-Dxd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study[EB/OL].[2024-03-15].
URL
|
| [16] |
Schmid P． Datopotamab deruxtecan (Dato-DXd) ＋ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ib/II study[EB/OL].[2024-03-15].
URL
|
| [17] |
Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132[J]. Front Oncol, 2022, 12: 951589.
|
| [18] |
Yongmei Y，Xinhong W，Quchang O，et al. Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in phase 2 study[EB/OL].[2024-03-15].
URL
|
| [19] |
Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study[J]. J Clin Oncol, 2020, 38(17): 1887-1896.
|
| [20] |
Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Ann Oncol, 2023, 34(8): 645-659.
|
| [21] |
Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin Cancer Res, 2016, 22(20): 5097-5108.
|
| [22] |
Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
|
| [23] |
Shi F, Liu Y, Zhou X, et al. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy[J]. Drug Deliv, 2022, 29(1): 1335-1344.
|
| [24] |
Wang JY, Liu YJ, Zhang QY. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies[EB/OL].[2024-03-15].
URL
|
| [25] |
Gandullo-Sánchez L, Ocaña A, Pandiella A. HER3 in cancer: from the bench to the bedside[J]. J Exp Clin Cancer Res, 2022, 41(1): 310.
|
| [26] |
Koyama K, Ishikawa H, Abe M, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression[J]. PLoS One, 2022, 17(5): e0267027.
|
| [27] |
Krop IE, Masuda N, Mukohara T, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II trial[J]. J Clin Oncol, 2023, 41(36): 5550-5560.
|
| [28] |
Hamilton EP，Ololade D, Mythili S，et al. A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)[EB/OL].[2024-03-15].
URL
|
| [29] |
Taylor KM. The LIV-1 subfamily of Zinc transporters: from origins to present day discoveries[J]. Int J Mol Sci, 2023, 24(2)：1255.
|
| [30] |
Sussman D, Smith LM, Anderson ME, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer[J]. Mol Cancer Ther, 2014, 13(12): 2991-3000.
|
| [31] |
Tsai M, Han HS, Montero AJ，et al. Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer[EB/OL].[2024-03-15].
URL
|
| [32] |
Han H, Diab S, Alemany C，et al. Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer[EB/OL].[2024-03-15].
URL
|
| [33] |
Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer[J]. Immunol Rev, 2017, 276(1): 40-51.
|
| [34] |
Wu J，Zhang J，Li H，et al. First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors[EB/OL].[2024-03-15].
URL
|
| [35] |
Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy[J]. Eur J Pharmacol, 2021, 911: 174516.
|
| [36] |
Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models[J]. Cancer Res, 2016, 76(10): 3003-3013.
|
| [37] |
Zhou W, Fang P, Yu D, et al. Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of Nectin-4-expressing cancers[J]. Mol Cancer Ther, 2023, 22(8): 913-925.
|